Um guia para a prática | 25 JUN 21

Retenção urinária devido à obstrução benigna da próstata

Revisão sistemática e uma meta-análise sobre o manejo desta patologia masculina prevalente em homens idosos
Autor/a: Markos Karavitakis, Iason Kyriazis , Muhammad Imran Omar y col. EUR URO-8261 May 2019 Volume 75, Issue 5,
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

[1] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminol-ogy of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.

 [2] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminol-ogy in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Urology 2003;61:37–49.

[3] Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD. Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol 2008;180:47–54.

[4] Oelke M, Speakman MJ, Desgrandchamps F, Mamoulakis C. Acute urinary retention rates in the general male population and in adult men with lower urinary tract symptoms participating in pharma-cotherapy trials: a literature review. Urology 2015;86:654–65.

[5] Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005;47:494–8.

[6] Agrawal MS, Yadav A, Yadav H, Singh AK, Lavania P, Jaiman R. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary reten- tion caused by benign prostatic hyperplasia. Indian J Urol 2009;25:474–8.

[7] McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-releasealfuzosinandtrialwithoutcatheterafteracuteurinary retention: a prospective, placebo-controlled. BJU Int 1999;84:622–7.

[8] Shah T, Palit V, Biyani S, Elmasry Y, Puri R, Flannigan GM. Random-ised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 2002;42:329–32.

[9] Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the manage-ment of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354–7.

[10] Kumar S, Tiwari DP, Ganesamoni R, Singh SK. Prospective random-ized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention. Urology 2013;82:171–5.

[11] McNeill SA, Hargreave TB. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 2004;171:2316–20.

[12] Taube M, Gajraj H. Trial without catheter following acute retention of urine. Br J Urol 1989;63:180–2.

ç[13] Breum L, Klarskov P, Munck LK, Nielsen TH, Nordestgaard AG. Significance of acute urinary retention due to intravesical obstruc-tion. Scand J Urol Nephrol 1982;16:21–4.

[14] Michel MC, Goepel M. Lower urinary tract symptoms suggestive of benign prostatic obstruction-what's the long-term effectiveness of medical therapies? Eur Urol 2001;39(Suppl. 3):20–5.

[15] Kuiper JG, Bezemer ID, Driessen MT, et al. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. BMC Urol 2016;16:53

 [16] Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123–31.

[17] Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention National Prostatectomy Audit Steering Group. Br J Urol 1998;81:712–20.

18] Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1997;11:609–22.

19] Brasure M, Fink HA, Risk M, et al. Chronic urinary retention: comparative effectiveness and harms of treatments. Rockville, MD: Agency for Healthcare Research and Quality; 2014.

[20] Fisher E, Subramonian K, Omar MI. The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database Syst Rev 2014;6:Cd006744.

[21] Yoon PD, Chalasani V, Woo HH. Systematic review and meta-anal-ysis on management of acute urinary retention. Prostate Cancer Prostat Dis 2015;18:297–302.

[22] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.

[23] Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol 2011;29:205–10.

[24] Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6.

[25] Moher DL, Liberty A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

[26] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.

[27] Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 (updated March 2011). The Cochrane.

[28] Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011;64:1294–302.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022